Huisman, Menno V.
Teutsch, Christine
Lu, Shihai
Diener, Hans-Christoph
Dubner, Sergio J.
Halperin, Jonathan L.
Ma, Chang-Sheng
Rothman, Kenneth J.
Lohmann, Ragna
Gurusamy, Venkatesh Kumar
Bartels, Dorothee B.
Lip, Gregory Y. H.
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
https://doi.org/10.1007/s11239-023-02866-y
Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
https://doi.org/10.1007/s00392-022-02022-1
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
https://doi.org/10.1007/s00392-022-01996-2
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
https://doi.org/10.1016/j.ahj.2013.12.006
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
https://doi.org/10.1007/s00392-021-01957-1
Documents that mention this clinical trial
Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry
https://doi.org/10.1007/s11239-023-02866-y
Impact of early ablation of atrial fibrillation on long-term outcomes: results from phase II/III of the GLORIA-AF registry
https://doi.org/10.1007/s00392-022-02022-1
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry
https://doi.org/10.1007/s00392-022-01996-2
Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation
https://doi.org/10.1016/j.ahj.2013.12.006
Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry
https://doi.org/10.1007/s00392-021-01957-1
Funding for this research was provided by:
boehringer ingelheim
Article History
Received: 24 August 2021
Accepted: 18 October 2021
First Online: 16 March 2022
Declarations
:
: MVH reports grants from ZonMW Dutch Healthcare Fund, and grants and consultation honoraria from Boehringer Ingelheim, Pfizer/Bristol-Myers Squibb, Bayer Health Care, Aspen, and Daiichi-Sankyo. H-CD reports honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer, Portola, and WebMD Global. Financial support for research projects was provided by Boehringer Ingelheim. SJD reports consultancy fees for serving as a Steering Committee member for Boehringer Ingelheim and research grants from Abbott (St Jude Medical). JLH reports consulting fees/honoraria or research support from Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo Pharma, Janssen Pharmaceuticals, Johnson & Johnson, Medtronic, Pfizer, and Sanofi Aventis. C-SM reports consultancy fees/honoraria from Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, and Pfizer. KJR reports employment by RTI Health Solutions, an independent, non-profit research organization that does work for government agencies and pharmaceutical companies. RL, VKG, and CT report employment by Boehringer Ingelheim International GmbH. DBB reports past employment by Boehringer Ingelheim International GmbH and current employment by UCB pharma. SL reports past employment by Boehringer Ingelheim International GmbH. GYHL reports consultancy for Bayer/Janssen, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi Sankyo; and speaking for Bayer, Bristol-Myers Squibb/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi Sankyo; no fees are directly received personally.
: GLORIA-AF was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki and Good Epidemiological Practice and Good Pharmacoepidemiology Practices, and the protocol was approved by the European Medicines Agency and institutional review boards at each participating site.
: Patients provided written informed consent.